ATE287953T1 - Persephin und verwandte wachstumsfaktoren - Google Patents

Persephin und verwandte wachstumsfaktoren

Info

Publication number
ATE287953T1
ATE287953T1 AT97917509T AT97917509T ATE287953T1 AT E287953 T1 ATE287953 T1 AT E287953T1 AT 97917509 T AT97917509 T AT 97917509T AT 97917509 T AT97917509 T AT 97917509T AT E287953 T1 ATE287953 T1 AT E287953T1
Authority
AT
Austria
Prior art keywords
persephin
methods
growth factors
mouse
neurturin
Prior art date
Application number
AT97917509T
Other languages
English (en)
Inventor
Eugene M Johnson Jr
Jeffrey D Milbrandt
Paul T Kotzbauer
Patricia A Lampe
Original Assignee
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington filed Critical Univ Washington
Application granted granted Critical
Publication of ATE287953T1 publication Critical patent/ATE287953T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
AT97917509T 1996-03-14 1997-03-14 Persephin und verwandte wachstumsfaktoren ATE287953T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61594496A 1996-03-14 1996-03-14
PCT/US1997/003461 WO1997033911A1 (en) 1996-03-14 1997-03-14 Persephin and related growth factors

Publications (1)

Publication Number Publication Date
ATE287953T1 true ATE287953T1 (de) 2005-02-15

Family

ID=24467424

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97917509T ATE287953T1 (de) 1996-03-14 1997-03-14 Persephin und verwandte wachstumsfaktoren

Country Status (10)

Country Link
US (4) US6232449B1 (de)
EP (1) EP0886651B1 (de)
JP (1) JP2000507813A (de)
AT (1) ATE287953T1 (de)
AU (1) AU716846B2 (de)
CA (1) CA2225913A1 (de)
DE (1) DE69732350T2 (de)
ES (1) ES2237793T3 (de)
NZ (1) NZ329482A (de)
WO (1) WO1997033911A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5739307A (en) * 1995-08-28 1998-04-14 Washington University Polynucleotide encoding neurturin neurotrophic factor
US6222022B1 (en) * 1996-03-14 2001-04-24 Washington University Persephin and related growth factors
US6716600B1 (en) * 1996-03-14 2004-04-06 Washington University Persephin and related growth factors
JP2000507813A (ja) * 1996-03-14 2000-06-27 ワシントン ユニヴァーシティー ペルセフィン及び関連成長因子
DE19816186A1 (de) * 1998-04-14 1999-10-21 Univ Muenchen L Maximilians GDNF-kodierende DNA, Teile davon und GDNF-Varianten
WO2000006731A2 (en) * 1998-07-31 2000-02-10 Washington University PERSEPHIN ARF, A PROTEIN ENCODED BY UNSPLICED PERSEPHIN mRNA
HUP0103419A3 (en) * 1998-08-21 2004-06-28 Saarma Mart The use of glial cell line-derived neurotrophic factor family-related compounds for regulating spermatogenesis and for preparing male contraceptives
US6284540B1 (en) * 1998-09-29 2001-09-04 Washington University Artemin, a novel neurotrophic factor
FI991197A0 (fi) * 1999-05-27 1999-05-27 Mart Saarma Neurotrooppiset tekijät lantionalueen ääreishermoston toimintahäiriön hoitamisessa
US6866851B1 (en) * 1999-12-28 2005-03-15 Washington University GFRα1-RET specific agonists and methods therefor
FI20000403A0 (fi) * 2000-02-22 2000-02-22 Hannu Sariola GDNF perhesukuisten yhdisteiden käyttö kivessyövän hoitoon tarkoitettujen tuotteiden valmistamiseksi
WO2010144696A1 (en) 2009-06-11 2010-12-16 Burnham Institute For Medical Research Directed differentiation of stem cells
US9821026B2 (en) * 2012-06-28 2017-11-21 Instituto De Medicina Molecular Use of RET agonist molecules for haematopoietic stem cell expansion protocols and transplantation therapy and a RET agonist kit

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5011914A (en) 1989-01-05 1991-04-30 Collins Franklin D Purified ciliary neurotrophic factor
US5141856A (en) 1989-01-05 1992-08-25 Synergen, Inc. Expression of purified ciliary neurotrophic factor
US5260417A (en) * 1989-04-03 1993-11-09 Genetics Institute, Inc. Megakaryocyte growth promoting activity protein
US5235043A (en) 1990-04-06 1993-08-10 Synergen, Inc. Production of biologically active, recombinant members of the ngf/bdnf family of neurotrophic proteins
MX9205293A (es) 1991-09-20 1993-05-01 Syntex Sinergen Neuroscience J Factores neurotrofico derivado del glial
AU692181B2 (en) 1993-09-01 1998-06-04 Start Technology Partnership Neuron regulatory factor for promoting neuron survival
AU1443095A (en) 1993-12-22 1995-07-10 University Of Medicine And Dentistry Of New Jersey Novel nucleic acid sequences isolated from glial cells
US5739307A (en) 1995-08-28 1998-04-14 Washington University Polynucleotide encoding neurturin neurotrophic factor
JP2000507813A (ja) * 1996-03-14 2000-06-27 ワシントン ユニヴァーシティー ペルセフィン及び関連成長因子

Also Published As

Publication number Publication date
EP0886651A4 (de) 2001-01-10
ES2237793T3 (es) 2005-08-01
CA2225913A1 (en) 1997-09-18
EP0886651A1 (de) 1998-12-30
WO1997033911A1 (en) 1997-09-18
EP0886651B1 (de) 2005-01-26
US6232449B1 (en) 2001-05-15
DE69732350T2 (de) 2005-12-22
US6692943B1 (en) 2004-02-17
AU716846B2 (en) 2000-03-09
AU2580497A (en) 1997-10-01
NZ329482A (en) 2000-05-26
US6645937B1 (en) 2003-11-11
US6403335B1 (en) 2002-06-11
DE69732350D1 (de) 2005-03-03
JP2000507813A (ja) 2000-06-27

Similar Documents

Publication Publication Date Title
ATE315578T1 (de) Neuriturin und verwandte wachstumsfaktoren
DE69732350D1 (de) Persephin und verwandte wachstumsfaktoren
ATE288447T1 (de) Methode zur behandlung von alzheimer mit einem von einer gliazelllinie stammenden neurotrophen protein (gdnf)
ATE315581T1 (de) Humanes persephin
DE69711894T2 (de) Lipoxinverbindungen und deren verwendung zur behandlung der zellenwucherungsstörung
AU3472997A (en) Ret ligand (retl) for stimulating neural and renal growth
ATE256475T1 (de) Verwendung von follistatin zur herstellung eines arzneimittels zur behandlung von muskuläre krankheiten
DE69840403D1 (de) System zum transfer und zur expression von heterologen genen ins knochenmark in vivo
DE69921156D1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
AU1615599A (en) Differentiation of adipose stromal cells into osteoblasts and uses thereof
LV10308A (lv) Ciliarais neirotropais faktors
ATE267247T1 (de) Reagenz und verfahren zur inhibierung der n-ras expression
EE200100472A (et) Polüpeptiid, antikehad, lahustuv polüpeptiid, polü- või oligonukleotiid ja meetod diferentsiaalseltekspresseerunud DNA järjestuste spetsiifiliseks identifitseerimiseks
Iimura et al. Changes in homeobox-containing gene expression during ectopic bone formation induced by bone morphogenetic protein
DK87190A (da) Fremgangsmaade til at regulere plantevaekst under anvendelse af svovlholdige organiske syrer
KR19990036081A (ko) 인간 엠피52 에이알지 단백질
RU2003123108A (ru) Мутантные формы человеческого белка fgf23, снижающие содержание фосфора в крови
Kotze et al. An exon 4 mutation identified in the majority of South African familial hypercholesterolaemics.
ATE227998T1 (de) Verwendung von substituierten dextranen zur behandlung von schädigungen des nervensystems, und fraktionen mit erhöhtem heparansulfat-gehalt
DE3687241T2 (de) Gewebetumorwachstumsinhibitoren, verfahren zur herstellung und verwendungen.
Wirtz et al. In vivo and in vitro noncovalent association of excised alpha 1 (I) amino-terminal propeptides with mutant pN alpha 2 (I) collagen chains in native mutant collagen in a case of Ehlers-Danlos syndrome, type VII.
Espaillat et al. Expression of fibronectin isoforms in rat cornea after an epithelial-scrape wound
WO1999025721B1 (en) Detection and treatment of retinal degenerative disease
Takenouchi et al. Chordoma of Spine above Sacrum-Surgical Treatment in 2 Cases
RU96104372A (ru) НОВЫЙ ФАКТОР РОСТА / ДИФФЕРЕНЦИАЦИИ TGF-β--СЕМЕЙСТВА

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties